With the United States Trade Representative (USTR)'s latest review of Section 301 tariff exclusions concluding this week, North American Tier-1 Medical OEMs are aggressively pursuing "Non-China Sourcing" to safeguard their supply chains. SINNHONG’s Vietnam-based production hub has emerged as a critical gateway, offering Landed-Cost Optimized and Tariff-Exempt medical cable assemblies that comply with both FDA and EU MDR transparency requirements.
The 2026 clinical landscape is dominated by AI-Enhanced Diagnostics and Autonomous Robotic Surgery. SINNHONG is at the forefront of this shift, providing:
Microsurgical Robotic Harnesses: Engineered for 10 million+ flex cycles, supporting the high-precision movement of AI-guided suturing arms.
Pulse Field Ablation (PFA) Catheter Links: Delivering high-voltage pulse stability for next-generation cardiac mapping and ablation procedures.
Hospital-at-Home (HaH) Interconnects: Specialized micro-interconnects for smart wearable ECG patches and continuous glucose monitors (CGM) designed for decentralized care.
"In the 2026 medical market, reliability is non-negotiable," stated SINNHONG’s Director of Medical OEM Manufacturing. "Our transition to the ISO 13485:2026 standard ensures that every autoclave-safe overmolded harness we produce features full digital traceability. By combining biocompatible USP Class VI materials with our Vietnam-based duty-free advantage, we are providing a resilient, high-performance solution for the next generation of life-saving technology."
As the industry pivots toward minimally invasive surgery (MIS 2.0), SINNHONG’s commitment to IPC-A-620 Class 3 quality ensures that global MedTech innovators can scale their AI diagnostic tools and surgical platforms without geopolitical or technical bottlenecks.
sales@sinnhong.com
Whatsapp: 8613543700314
Send us message